ArticleCancer research2016

Trametinib Drives T-cell-Dependent Control of KRAS-Mutated Tumors by Inhibiting Pathological Myelopoiesis.

Michael J Allegrezza et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.